The Experts below are selected from a list of 2436 Experts worldwide ranked by ideXlab platform
Ellen W Freeman - One of the best experts on this subject based on the ideXlab platform.
-
continuous oral levonorgestrel ethinyl estradiol for treating Premenstrual Dysphoric Disorder
Contraception, 2012Co-Authors: Uriel Halbreich, Richard Bergeron, Ellen W Freeman, Lee S Cohen, Andrea J. Rapkin, Gary S Grubb, Lynne Smith, Sebastian Mirkin, Ginger D ConstantineAbstract:Abstract Background The study was conducted to investigate continuous daily levonorgestrel 90 mcg/ethinyl estradiol 20 mcg (LNG/EE) on Premenstrual Dysphoric Disorder (PMDD). Study Design In this multicenter, randomized, double-blind, placebo-controlled study, women with PMDD received LNG/EE ( n =186) or placebo ( n =181) daily for 112 days and completed the Daily Record of Severity of Problems (DRSP). Results Mean DRSP change from baseline to late luteal phase was significantly greater with LNG/EE than placebo at the late luteal phase of the first estimated cycle (���30.52��1.73 [SE] vs. ���22.47��1.77; p Conclusions Continuous daily LNG 90 mcg/EE 20 mcg was well tolerated and may be useful for managing the physical, psychological and behavioral symptoms and loss of work productivity related to PMDD.
-
Are there Differential Symptom Profiles that Improve in Response to Different Pharmacological Treatments of Premenstrual Syndrome/Premenstrual Dysphoric Disorder?
CNS Drugs, 2006Co-Authors: Uriel Halbreich, Kimberly A Yonkers, Elias Eriksson, Torbjorn Backstrom, Pm Shaughn O’brien, Ellen W FreemanAbstract:Current evidence suggests that the accepted treatments for Premenstrual syndrome (PMS)/Premenstrual Dysphoric Disorder (PMDD) have similar overall efficacy. While these treatments are more effective than placebo, response rates associated with them are far from satisfactory (
-
are there differential symptom profiles that improve in response to different pharmacological treatments of Premenstrual syndrome Premenstrual Dysphoric Disorder
CNS Drugs, 2006Co-Authors: Uriel Halbreich, Kimberly A Yonkers, Elias Eriksson, Torbjorn Backstrom, P Shaughn M Obrien, Ellen W FreemanAbstract:Current evidence suggests that the accepted treatments for Premenstrual syndrome (PMS)/Premenstrual Dysphoric Disorder (PMDD) have similar overall efficacy. While these treatments are more effective than placebo, response rates associated with them are far from satisfactory (<60%), such that, irrespective of treatment modality, there remain a significant number of women who are unresponsive to current conventional pharmacological therapy.
-
Premenstrual syndrome and Premenstrual Dysphoric Disorder definitions and diagnosis
Psychoneuroendocrinology, 2003Co-Authors: Ellen W FreemanAbstract:Because of the prevalence, chronicity and distress caused by Premenstrual symptoms (PMS), diagnosis and effective treatments are important information for clinicians. The DSM-IV requires at least five specified symptoms for Premenstrual Dysphoric Disorder (PMDD), a severe Dysphoric form of PMS, while the ICD-10 requires only one distressing symptom for a diagnosis of PMS. Many women who seek treatment fall between these two diagnostic approaches, and standard diagnostic criteria for clinically significant PMS are needed. A diagnosis of PMS consists of determining the timing of the symptoms in relation to menses, meaningful change between post- and Premenstrual symptom severity and a clinically significant severity of the symptoms. A differential diagnosis to distinguish PMS from other medical and psychiatric conditions is important for appropriate treatment. No hormone or laboratory test indicates a PMS diagnosis. The current diagnostic standard requires confirmation of subjective symptom reports by prospective daily diaries. Diagnostic criteria for PMS must recognize the broad range of symptoms, the temporal pattern of the symptoms and the critical issue of symptom severity, which differentiates clinically significant PMS from normal menstrual cycle changes.
-
efficacy of intermittent luteal phase sertraline treatment of Premenstrual Dysphoric Disorder
Obstetrics & Gynecology, 2002Co-Authors: Uriel Halbreich, Kimberly A Yonkers, Richard Bergeron, Ellen W Freeman, Anna L Stout, Lee S CohenAbstract:Abstract OBJECTIVE: Premenstrual Dysphoric Disorder is a menstrually related Disorder that intermittently causes disabling emotional, behavioral, and physical symptoms. The goal of the current study was to evaluate the efficacy and tolerability of sertraline for Premenstrual Dysphoric Disorder when treatment was limited to the luteal phase. METHODS: Two hundred eighty-one women who met Diagnostic and Statistical Manual of Mental Disorders (4th edition) criteria for Premenstrual Dysphoric Disorder and who completed two prospective screening cycles and one single-blind placebo cycle were randomized to three cycles of double-blind, luteal phase treatment with either a placebo or sertraline in a flexible daily dose of 50–100 mg. Outcome measures included the Daily Record of Severity of Problems and the Clinical Global Impression Severity and Improvement scales. RESULTS: Luteal phase treatment with sertraline was significantly superior to the placebo, as demonstrated by end- point analysis of Clinical Global Impression Improvement scale scores (sertraline, 2.3 ± 1.1, versus placebo, 2.7 ± 1.1; P CONCLUSION: Sertraline was significantly more effective than a placebo and was well tolerated as a treatment for Premenstrual Dysphoric Disorder when administered intermittently during the luteal phase of the menstrual cycle.
Kimberly A Yonkers - One of the best experts on this subject based on the ideXlab platform.
-
Premenstrual Dysphoric Disorder evidence for a new category for dsm 5
American Journal of Psychiatry, 2012Co-Authors: Neill C Epperson, Peter Schmidt, Elias Eriksson, Meir Steiner, Ann S Hartlage, Ian Jones, Kimberly A YonkersAbstract:Premenstrual Dysphoric Disorder, which affects 2%–5% of premenopausal women, was included in Appendix B of DSM-IV, “Criterion Sets and Axes Provided for Further Study.” Since then, aided by the inclusion of specific and rigorous criteria in DSM-IV, there has been an explosion of research on the epidemiology, phenomenology, pathogenesis, and treatment of the Disorder. In 2009, the Mood Disorders Work Group for DSM-5 convened a group of experts to examine the literature on Premenstrual Dysphoric Disorder and provide recommendations regarding the appropriate criteria and placement for the Disorder in DSM-5. Based on thorough review and lengthy discussion, the work group proposed that the information on the diagnosis, treatment, and validation of the Disorder has matured sufficiently for it to qualify as a full category in DSM-5. A move to the position of category, rather than a criterion set in need of further study, will provide greater legitimacy for the Disorder and encourage the growth of evidence-based research, ultimately leading to new treatments.
-
criteria for Premenstrual Dysphoric Disorder secondary analyses of relevant data sets
Archives of General Psychiatry, 2012Co-Authors: Ann S Hartlage, Sally Freels, Nathan Gotman, Kimberly A YonkersAbstract:Context There is substantial information that Premenstrual Dysphoric Disorder (PMDD) is a clinically significant Disorder with biological underpinnings that differ from other psychiatric Disorders. However, data regarding the symptoms noted in DSM-IV and timing of their expression in the menstrual cycle have had little empirical support. Objective To provide evidence informing the definitional criteria for PMDD. Design Prospective surveys. Setting General community and clinical settings. Participants Two cohorts that included a representative sample and a self-identified treatment-seeking cohort. Main Outcome Measure Daily ratings of perimenstrual symptoms and functioning. Results Mood and physical symptoms were most severe and were accompanied by impairment in the 4 days before through the first 2 days of menses for the self-identified group and in the 3 days before through the first 3 days of menses in the community sample. The most problematic symptoms endorsed were those listed in DSM-IV, but depressed mood was less frequent than other affective symptoms. In the combined sample, 4 or more symptoms was the optimal cutoff point for maximizing both sensitivity and specificity when predicting impairment. Conclusions This is informative for DSM-5 in that the most symptomatic period typically includes the few days before through the first 3 days of menses rather than only the Premenstrual phase. Further, we validated the salience of PMDD symptoms included in DSM-IV. Although the number of symptoms most associated with distress and impairment differed between the 2 cohorts, results from the combined cohort suggest that 4 symptoms are linked with impairment from PMDD symptoms.
-
update on research and treatment of Premenstrual Dysphoric Disorder
Harvard Review of Psychiatry, 2009Co-Authors: Joanne Cunningham, Kimberly A Yonkers, Shaughn Obrien, Elias ErikssonAbstract:Many women in their reproductive years experience some mood, behavioral. or physical symptoms in the week prior to menses. Variability exists in the level of symptom burden in that some women experience mild symptoms, whereas a small minority experience severe and debilitating symptoms. For an estimated 5%-8% of premenopausal women, work or social functioning are affected by severe Premenstrual syndrome. Many women in this group meet diagnostic criteria for Premenstrual Dysphoric Disorder (PMDD). Among women who suffer from PMDD, mood and behavioral symptoms such as irritability, depressed mood, tension, and labile mood dominate. Somatic complaints, including breast tenderness and bloating, also can prove disruptive to women's overall functioning and quality of life. Recent evidence suggests that individual sensitivity to cyclical variations in levels of gonadal hormones may predispose certain women to experience these mood, behavioral, and somatic symptoms. Treatments include: antidepressants of the serotonin reuptake inhibitor class, taken intermittently or throughout the menstrual cycle; medications that suppress ovarian cyclicity; and newer oral contraceptives with novel progestins.
-
Are there Differential Symptom Profiles that Improve in Response to Different Pharmacological Treatments of Premenstrual Syndrome/Premenstrual Dysphoric Disorder?
CNS Drugs, 2006Co-Authors: Uriel Halbreich, Kimberly A Yonkers, Elias Eriksson, Torbjorn Backstrom, Pm Shaughn O’brien, Ellen W FreemanAbstract:Current evidence suggests that the accepted treatments for Premenstrual syndrome (PMS)/Premenstrual Dysphoric Disorder (PMDD) have similar overall efficacy. While these treatments are more effective than placebo, response rates associated with them are far from satisfactory (
-
are there differential symptom profiles that improve in response to different pharmacological treatments of Premenstrual syndrome Premenstrual Dysphoric Disorder
CNS Drugs, 2006Co-Authors: Uriel Halbreich, Kimberly A Yonkers, Elias Eriksson, Torbjorn Backstrom, P Shaughn M Obrien, Ellen W FreemanAbstract:Current evidence suggests that the accepted treatments for Premenstrual syndrome (PMS)/Premenstrual Dysphoric Disorder (PMDD) have similar overall efficacy. While these treatments are more effective than placebo, response rates associated with them are far from satisfactory (<60%), such that, irrespective of treatment modality, there remain a significant number of women who are unresponsive to current conventional pharmacological therapy.
Uriel Halbreich - One of the best experts on this subject based on the ideXlab platform.
-
continuous oral levonorgestrel ethinyl estradiol for treating Premenstrual Dysphoric Disorder
Contraception, 2012Co-Authors: Uriel Halbreich, Richard Bergeron, Ellen W Freeman, Lee S Cohen, Andrea J. Rapkin, Gary S Grubb, Lynne Smith, Sebastian Mirkin, Ginger D ConstantineAbstract:Abstract Background The study was conducted to investigate continuous daily levonorgestrel 90 mcg/ethinyl estradiol 20 mcg (LNG/EE) on Premenstrual Dysphoric Disorder (PMDD). Study Design In this multicenter, randomized, double-blind, placebo-controlled study, women with PMDD received LNG/EE ( n =186) or placebo ( n =181) daily for 112 days and completed the Daily Record of Severity of Problems (DRSP). Results Mean DRSP change from baseline to late luteal phase was significantly greater with LNG/EE than placebo at the late luteal phase of the first estimated cycle (���30.52��1.73 [SE] vs. ���22.47��1.77; p Conclusions Continuous daily LNG 90 mcg/EE 20 mcg was well tolerated and may be useful for managing the physical, psychological and behavioral symptoms and loss of work productivity related to PMDD.
-
Are there Differential Symptom Profiles that Improve in Response to Different Pharmacological Treatments of Premenstrual Syndrome/Premenstrual Dysphoric Disorder?
CNS Drugs, 2006Co-Authors: Uriel Halbreich, Kimberly A Yonkers, Elias Eriksson, Torbjorn Backstrom, Pm Shaughn O’brien, Ellen W FreemanAbstract:Current evidence suggests that the accepted treatments for Premenstrual syndrome (PMS)/Premenstrual Dysphoric Disorder (PMDD) have similar overall efficacy. While these treatments are more effective than placebo, response rates associated with them are far from satisfactory (
-
are there differential symptom profiles that improve in response to different pharmacological treatments of Premenstrual syndrome Premenstrual Dysphoric Disorder
CNS Drugs, 2006Co-Authors: Uriel Halbreich, Kimberly A Yonkers, Elias Eriksson, Torbjorn Backstrom, P Shaughn M Obrien, Ellen W FreemanAbstract:Current evidence suggests that the accepted treatments for Premenstrual syndrome (PMS)/Premenstrual Dysphoric Disorder (PMDD) have similar overall efficacy. While these treatments are more effective than placebo, response rates associated with them are far from satisfactory (<60%), such that, irrespective of treatment modality, there remain a significant number of women who are unresponsive to current conventional pharmacological therapy.
-
the diagnosis of Premenstrual syndromes and Premenstrual Dysphoric Disorder clinical procedures and research perspectives
Gynecological Endocrinology, 2004Co-Authors: Uriel HalbreichAbstract:Premenstrual syndromes (PMS) are quite prevalent among women of reproductive age. In up to 20% of women they are severe enough to warrant treatment, which is available and marketed as such. The impact of the cumulative burden of PMS is substantial and is in the same magnitude as affective Disorders. Nevertheless, the definitions and diagnoses of PMS are still fragmented, not widely accepted and, if accepted, not always applied in day-to-day clinical practice. In the present paper, the current diagnostic entities are critically reviewed, problems with the current definitions are delineated and a unified definition is proposed. For clinical purposes, the recommended clinical practical diagnostic process and differential diagnosis are described. For clinical trials of medications for treatment of PMS/Premenstrual Dysphoric Disorder, research diagnostic criteria, inclusion and exclusion criteria, as well as well-defined outcome measures, are of utmost importance; they are described here. The gaps of knowledge in the description and diagnosis of PMS are described, with suggestions for future directions for research.
-
the prevalence impairment impact and burden of Premenstrual Dysphoric Disorder pms pmdd
Psychoneuroendocrinology, 2003Co-Authors: Uriel Halbreich, Teri Pearlstein, Jeffrey T Borenstein, Linda S KahnAbstract:Currently it is estimated that 3-8% of women of reproductive age meet strict criteria for Premenstrual Dysphoric Disorder (PMDD). Assessment of published reports demonstrate that the prevalence of clinically relevant Dysphoric Premenstrual Disorder is probably higher. 13-18% of women of reproductive age may have Premenstrual Dysphoric symptoms severe enough to induce impairment and distress, though the number of symptoms may not meet the arbitrary count of 5 symptoms on the PMDD list. The impairment and lowered quality of life for PMDD is similar to that of dysthymic Disorder and is not much lower than major depressive Disorder. Nevertheless, PMS/PMDD is still under-recognized in large published epidemiological studies, as well as assessments of burden of disease. It is demonstrated here that the burden of PMS/PMDD as well as the disability adjusted life years (DALY) lost due to this repeated-cyclic Disorder is in the same magnitude as major recognized Disorders. Appropriate recognition of the Disorder and its impact should lead to treatment of more women with PMS/PMDD. Efficacious treatments are available. They should reduce individual suffering and impact on family, society, and economy.
Teri Pearlstein - One of the best experts on this subject based on the ideXlab platform.
-
Premenstrual Dysphoric Disorder
Medical Clinics of North America, 2019Co-Authors: Teresa Lanza Di Scalea, Teri PearlsteinAbstract:Premenstrual Dysphoric Disorder (PMDD) comprises emotional and physical symptoms and functional impairment that lie on the severe end of the continuum of Premenstrual symptoms. Women with PMDD have a differential response to normal hormonal fluctuations. This susceptibility may involve the serotonin system, altered sensitivity of the GABAA receptor to the neurosteroid allopregnanalone, and altered brain circuitry involving emotional and cognitive functions. Serotonin reuptake inhibitors are considered the first-line treatment. Second-line treatments include oral contraceptives containing drospirenone, other ovulation suppression methods, calcium, chasteberry, and cognitive-behavioral therapy.
-
Premenstrual Dysphoric Disorder burden of illness and treatment update
FOCUS, 2012Co-Authors: Teri Pearlstein, Meir SteinerAbstract:Five percent of menstruating women have severe Premenstrual symptoms and impairment of functioning defined as Premenstrual Dysphoric Disorder (PMDD). Clinically significant Premenstrual symptoms occur in at least an additional 20% of menstruating women. The diagnosis of PMDD should be confirmed by prospective symptom charting over 2 menstrual cycles to confirm the timing of the symptoms and to rule out other diagnoses. The burden of illness of PMDD includes disruption of parenting and partner relationships and decreased productivity in work roles. In addition, women with PMDD have increased use of health care services such as clinician visits and increased use of prescription medications and over-the-counter preparations. The etiology of PMDD is multifactorial. In particular, dysregulation of the serotonin and allopregnanolone systems is implicated. Several effective treatment options exist, including serotonergic antidepressant medications and an oral contraceptive that contains ethinyl estradiol and dro...
-
Premenstrual Dysphoric Disorder burden of illness and treatment update
Journal of Psychiatry & Neuroscience, 2008Co-Authors: Teri Pearlstein, Meir SteinerAbstract:Five percent of menstruating women have severe Premenstrual symptoms and impairment of functioning defined as Premenstrual Dysphoric Disorder (PMDD). Clinically significant Premenstrual symptoms occur in at least an additional 20% of menstruating women. The diagnosis of PMDD should be confirmed by prospective symptom charting over 2 menstrual cycles to confirm the timing of the symptoms and to rule out other diagnoses. The burden of illness of PMDD includes disruption of parenting and partner relationships and decreased productivity in work roles. In addition, women with PMDD have increased use of health care services such as clinician visits and increased use of prescription medications and over-the-counter preparations. The etiology of PMDD is multifactorial. In particular, dysregulation of the serotonin and allopregnanolone systems is implicated. Several effective treatment options exist, including serotonergic antidepressant medications and an oral contraceptive that contains ethinyl estradiol and drosperinone. In addition, other hormones that suppress ovulation, anxiolytics, cognitive therapy, chasteberry and calcium may be helpful.
-
treatment of Premenstrual Dysphoric Disorder with a new drospirenone containing oral contraceptive formulation
Contraception, 2005Co-Authors: Teri Pearlstein, Gloria Bachmann, Howard A Zacur, Kimberly A YonkersAbstract:Abstract Purpose This multicenter, double-blind, placebo-controlled crossover study evaluated the efficacy of a new oral contraceptive (OC) formulation containing drospirenone 3 mg and ethinyl estradiol (EE) 20 ��g in treating symptoms of Premenstrual Dysphoric Disorder (PMDD). Method The OC formulation or placebo was administered for 24 days in a 28-day cycle (24/4), rather than the usual 21-day active treatment, 7-day inert-pill regimen. Participants ( N =64) were randomized to either study treatment for three cycles and then after a washout period of one treatment-free cycle switched to the alternate treatment. Results The mean decrease from baseline for total Daily Record of Severity of Problems (DRSP) scores while using drospirenone/EE was significantly greater than for placebo (���12.47, 95% CI=���18.28, ���6.66; p Conclusion Drospirenone/EE, given in a 24/4 regimen, was superior to placebo for improving symptoms associated with PMDD.
-
pretreatment pattern of symptom expression in Premenstrual Dysphoric Disorder
Journal of Affective Disorders, 2005Co-Authors: Teri Pearlstein, Kimberly A Yonkers, Rana Fayyad, John A GillespieAbstract:Abstract Background Use of intermittent dosing strategies for the treatment of Premenstrual Dysphoric Disorder (PMDD) highlights the need for detailed empirical data on the onset, duration and pattern of symptom expression in women suffering from PMDD. Method Data were analyzed from 276 women who met DSM-IV criteria for PMDD and prospectively charted two menstrual cycles prior to commencing sertraline treatment. The presence and severity of PMDD symptoms were measured using the Daily Record of Severity of Problems (DRSP). Results The most frequent PMDD symptoms (moderate-to-severe for ≥3 days) included anger/irritability (76%), anxiety/tension (71%), tired/lethargic (58%), and mood swings (58%). Mean DRSP scores peaked at day −2 (2 days prior to the onset of menses), but the within-patient day of onset of PMDD-level symptoms was highly variable, differing from cycle-to-cycle by ≥4 days in 45% of women. Similarly, the within-patient duration of PMDD symptoms varied from cycle-to-cycle by 3 or more days in ≥50% of women. Depending on the criteria used, 1 day after the onset of menstruation, 34–46% of women continued to report moderate to severe symptoms. Limitation Women in this sample were recruited for participation in a treatment study, and the results may not generalize to women with PMDD in the community. Conclusion The results of this analysis found significant within-patient variability in the time-to-onset and offset of PMDD symptoms, as well as their duration. The temporal pattern and high degree of within-patient variability across menstrual cycles of PMDD symptoms may have treatment implications.
Elias Eriksson - One of the best experts on this subject based on the ideXlab platform.
-
Premenstrual Dysphoric Disorder evidence for a new category for dsm 5
American Journal of Psychiatry, 2012Co-Authors: Neill C Epperson, Peter Schmidt, Elias Eriksson, Meir Steiner, Ann S Hartlage, Ian Jones, Kimberly A YonkersAbstract:Premenstrual Dysphoric Disorder, which affects 2%–5% of premenopausal women, was included in Appendix B of DSM-IV, “Criterion Sets and Axes Provided for Further Study.” Since then, aided by the inclusion of specific and rigorous criteria in DSM-IV, there has been an explosion of research on the epidemiology, phenomenology, pathogenesis, and treatment of the Disorder. In 2009, the Mood Disorders Work Group for DSM-5 convened a group of experts to examine the literature on Premenstrual Dysphoric Disorder and provide recommendations regarding the appropriate criteria and placement for the Disorder in DSM-5. Based on thorough review and lengthy discussion, the work group proposed that the information on the diagnosis, treatment, and validation of the Disorder has matured sufficiently for it to qualify as a full category in DSM-5. A move to the position of category, rather than a criterion set in need of further study, will provide greater legitimacy for the Disorder and encourage the growth of evidence-based research, ultimately leading to new treatments.
-
update on research and treatment of Premenstrual Dysphoric Disorder
Harvard Review of Psychiatry, 2009Co-Authors: Joanne Cunningham, Kimberly A Yonkers, Shaughn Obrien, Elias ErikssonAbstract:Many women in their reproductive years experience some mood, behavioral. or physical symptoms in the week prior to menses. Variability exists in the level of symptom burden in that some women experience mild symptoms, whereas a small minority experience severe and debilitating symptoms. For an estimated 5%-8% of premenopausal women, work or social functioning are affected by severe Premenstrual syndrome. Many women in this group meet diagnostic criteria for Premenstrual Dysphoric Disorder (PMDD). Among women who suffer from PMDD, mood and behavioral symptoms such as irritability, depressed mood, tension, and labile mood dominate. Somatic complaints, including breast tenderness and bloating, also can prove disruptive to women's overall functioning and quality of life. Recent evidence suggests that individual sensitivity to cyclical variations in levels of gonadal hormones may predispose certain women to experience these mood, behavioral, and somatic symptoms. Treatments include: antidepressants of the serotonin reuptake inhibitor class, taken intermittently or throughout the menstrual cycle; medications that suppress ovarian cyclicity; and newer oral contraceptives with novel progestins.
-
Placebo-Controlled Trial Comparing Intermittent and Continuous Paroxetine in Premenstrual Dysphoric Disorder
Neuropsychopharmacology, 2007Co-Authors: Mikael Landén, Hans Nissbrandt, Christer Allgulander, Karin Sörvik, Christina Ysander, Elias ErikssonAbstract:Serotonin reuptake inhibitors (SRIs) do not have to be administered continuously to be effective for Premenstrual Dysphoric Disorder (PMDD), but can be given during luteal phases only. This is of practical importance, but also of theoretical interest since it suggests that the onset of action of SRIs is shorter in PMDD than in, for example depression. In this study, both continuous and intermittent SRI administration was compared with placebo, with the special purpose of analyzing if different PMDD symptoms respond differently depending on the treatment regimen. To this end, women meeting slightly modified DSM-IV criteria for PMDD (mean±SD age, 37±6.3 years) were treated for three menstrual cycles with paroxetine continuously, paroxetine during the luteal phase only, or placebo, the population completing at least one treatment cycle comprising 55–56 subjects per group. Continuous treatment with paroxetine reduced Premenstrual symptoms effectively with a response rate of 85%. The effect size was highest for irritability (1.4) and lowest for lack of energy (0.5). Intermittent treatment was as effective as continuous treatment in reducing irritability, affect lability, and mood swings, but had a somewhat weaker effect on depressed mood and somatic symptoms. The study indicates that the response rate when treating PMDD with SRIs is high, and that irritability is a key target symptom. Symptoms such as irritability, affect lability, and mood swings appear to be more inclined to respond rapidly to SRIs, enabling intermittent treatment, than are, for example, the somatic symptoms.
-
Are there Differential Symptom Profiles that Improve in Response to Different Pharmacological Treatments of Premenstrual Syndrome/Premenstrual Dysphoric Disorder?
CNS Drugs, 2006Co-Authors: Uriel Halbreich, Kimberly A Yonkers, Elias Eriksson, Torbjorn Backstrom, Pm Shaughn O’brien, Ellen W FreemanAbstract:Current evidence suggests that the accepted treatments for Premenstrual syndrome (PMS)/Premenstrual Dysphoric Disorder (PMDD) have similar overall efficacy. While these treatments are more effective than placebo, response rates associated with them are far from satisfactory (
-
are there differential symptom profiles that improve in response to different pharmacological treatments of Premenstrual syndrome Premenstrual Dysphoric Disorder
CNS Drugs, 2006Co-Authors: Uriel Halbreich, Kimberly A Yonkers, Elias Eriksson, Torbjorn Backstrom, P Shaughn M Obrien, Ellen W FreemanAbstract:Current evidence suggests that the accepted treatments for Premenstrual syndrome (PMS)/Premenstrual Dysphoric Disorder (PMDD) have similar overall efficacy. While these treatments are more effective than placebo, response rates associated with them are far from satisfactory (<60%), such that, irrespective of treatment modality, there remain a significant number of women who are unresponsive to current conventional pharmacological therapy.